NDAINTRAVENOUSPOWDER1 Generic Approved
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KHAPZORY (levoleucovorin) is an intravenous powder formulation of the active isomer of leucovorin, a folate analog used to potentiate fluorouracil chemotherapy and reduce methotrexate toxicity. It is administered as a supportive agent in cancer chemotherapy regimens. The drug enhances the efficacy of certain cytotoxic agents by providing reduced folate cofactors.
Peak12.4 years to LOE
Product is in peak commercial stage with low per-unit pricing typical of generic-competitive oncology supportive care; team likely mid-sized with focus on operational efficiency and market access.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
Started Apr 2024
41 enrolled
Metastatic Adenocarcinoma of the Pancreas
Career Relevance
Working on KHAPZORY offers stable, operations-focused career growth in a mature market segment; there are currently no posted roles, suggesting a lean, efficient team structure. This product suits professionals seeking to optimize profitability and market position in supportive oncology rather than launch innovation.
Medical Science Liaison
Worked on KHAPZORY at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.